RDGL — VIVOS INC

OTC · Health Care · Health Care Equipment & Supplies · CIK 1449349 ·
Last close
$0.07
Market Cap
$34.42M
52W High
$0.09
52W Low
$0.06
ADV30
1,755,754
Next earnings
Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents; Duncan Chiller, a general laboratory equipment for non-water localized chilling; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Peltier Chiller brands. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Kennewick, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 36,068 -8,018 -545,492 -1,184,845 2,950,505 2,525,782 253,195
Dec 2025 24,752 -3,105 -1,095,719 -1,078,514 1,867,583 1,558,525 206,743
Sep 2025 1,879 -12,815 -531,023 -507,294 2,295,185 2,202,109 112,693
Jun 2025 15,000 -34,753 -674,772 -645,513 2,775,556 2,660,590 96,458

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,057,743
Investing CF
Financing CF
$1,506,905
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$0.00
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-88,427,246
Inventory
$57,257
Receivables
$22,331
ST Investments
EBIT TTM
$-3,165,046
Pretax Income TTM
$-3,066,017
Interest Exp TTM
Analysts

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 68,379 -3,165,047 -3,066,017 1,867,583 206,743 -2,057,743
Dec 2024 27,995 -2,604,384 -2,910,448 2,233,456 86,209 -1,684,039
Dec 2023 19,500 -2,793,146 -2,894,753 1,610,124 245,004 -1,293,023
Dec 2022 36,499 -2,517,749 -2,470,161 1,742,736 81,692 -1,120,058

Peers — same industry

TickerNameMarket CapLastDaily %
NMTC NEUROONE MEDICAL TECHNOLOGIES Corp $33.36M $3.87
CODX Co-Diagnostics, Inc. $33.32M $9.11
MLSS MILESTONE SCIENTIFIC INC. $32.77M $0.37
FOFA FAMILY OFFICE OF AMERICA, INC. $36.42M $1.20
TELA TELA Bio, Inc. $36.44M $0.81

News headlines (Yahoo Finance, 1h cache)

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
2026-05-20 20:10 · Yahoo
Vivos Therapeutics Reports Full Year 2025 Financial Results
2026-04-15 20:20 · Yahoo
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
2026-04-15 12:45 · Yahoo
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
2026-04-07 12:45 · Yahoo
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
2026-03-26 12:45 · Yahoo
Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy
2026-03-17 12:45 · Yahoo
Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites
2026-02-17 13:30 · Yahoo
Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™
2026-02-10 13:30 · Yahoo
Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies
2026-02-05 13:45 · Yahoo
Vivos Inc Updates Human Therapy Progress in India
2026-02-03 13:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.